These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20332341)

  • 1. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.
    Rong SL; Leonard SN
    Ann Pharmacother; 2010 May; 44(5):844-50. PubMed ID: 20332341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Leonard SN; Rossi KL; Newton KL; Rybak MJ
    J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).
    Voss A; Mouton JW; van Elzakker EP; Hendrix RG; Goessens W; Kluytmans JA; Krabbe PF; de Neeling HJ; Sloos JH; Oztoprak N; Howe RA; Walsh TR
    Ann Clin Microbiol Antimicrob; 2007 Sep; 6():9. PubMed ID: 17892555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus.
    Ruef C
    Infection; 2004 Dec; 32(6):315-27. PubMed ID: 15597220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
    Sakoulas G; Gold HS; Cohen RA; Venkataraman L; Moellering RC; Eliopoulos GM
    J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
    Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.
    Tsuji BT; Rybak MJ
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):73-7. PubMed ID: 16368477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.
    Eguia JM; Liu C; Moore M; Wrone EM; Pont J; Gerberding JL; Chambers HF
    Clin Infect Dis; 2005 Jun; 40(11):1617-24. PubMed ID: 15889359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.
    Wootton M; MacGowan AP; Walsh TR; Howe RA
    J Clin Microbiol; 2007 Feb; 45(2):329-32. PubMed ID: 17108069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
    Piérard D; Vandenbussche H; Verschraegen I; Lauwers S
    Pathol Biol (Paris); 2004 Oct; 52(8):486-8. PubMed ID: 15465269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy].
    Lecaillon E; Gueudet P; Wooton M; Walsh TR; Macgowan AP; Jones ME
    Pathol Biol (Paris); 2002 Nov; 50(9):525-9. PubMed ID: 12490414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
    Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
    J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains.
    Tenover FC
    Int J Antimicrob Agents; 2010 Oct; 36(4):303-6. PubMed ID: 20674281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.